Orgenesis Inc. Gross Margin

Gross Margin of ORGS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Gross Margin growth rates and interactive chart. Gross profit margin shows the percentage of revenue that exceeds a company's costs of goods sold. It illustrates how well a company is generating revenue from the costs involved in producing their products and services. The higher the margin, the more effective the company's management is in generating revenue for each dollar of cost. Gross profit margin is calculated by subtracting the cost of goods sold from total revenue for the period and dividing that number by revenue. If a company has $200 million in revenue and $80 million in cost of goods sold, the gross margin is 60%.


Highlights and Quick Summary

  • Gross Margin for the quarter ending June 29, 2021 was 7.76% (a -77.66% decrease compared to previous quarter)
  • Year-over-year quarterly Gross Margin decreased by -102.57%
  • Annual Gross Margin for 2020 was -997.57% (a 284.52% increase from previous year)
  • Annual Gross Margin for 2019 was -259.43% (a -964.48% decrease from previous year)
  • Annual Gross Margin for 2018 was 30.01% (a -28.51% decrease from previous year)
  • Twelve month Gross Margin ending June 29, 2021 was -192.18% (a -58.42% decrease compared to previous quarter)
  • Twelve month trailing Gross Margin decreased by -62.46% year-over-year
Trailing Gross Margin for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
-192.18% -462.16% -997.57% -511.9%
Visit stockrow.com/ORGS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Gross Margin of Orgenesis Inc.

Most recent Gross Marginof ORGS including historical data for past 10 years.

Interactive Chart of Gross Margin of Orgenesis Inc.

Orgenesis Inc. Gross Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 7.76% 34.74%
2020 -1955.71% -302.02% -1327.27% -159.48% -997.57%
2019 -152.55% -103.57% -172.33% -1237.71% -259.43%
2018 36.96% 45.73% 44.95% 37.63% 30.01%
2017 27.13% 50.91% -2.86% 15.27%
2016 -2.86% 1.08% -73.5% -73.5% -45.02%
2015 -30.46%

Business Profile of Orgenesis Inc.

Sector: Healthcare
Industry: Biotechnology
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. Orgenesis Inc. has a collaboration agreement with Savicell Diagnostics Ltd. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.